Press Releases

ISPB Partners with Horizon Therapeutics to Provide Grants for Low Vision Equipment for Illinois Residents in Need

(PRESS RELEASE) CHICAGO, IL — As part of February’s Low Vision Awareness Month, nonprofit organization Illinois Society for the Prevention of Blindness (ISPB) is partnering with Horizon Therapeutics, a global biotechnology company focused on rare, autoimmune and severe inflammatory diseases, to provide much-needed low vision equipment to the underserved in Illinois as part of the ISPB Low Vision Equipment Reimbursement Program. The program provides reimbursement for low vision aids, scleral lenses, and eyeglasses, to those who cannot otherwise afford them. Horizon is supporting the program with a donation of $50,000.

Low Vision is defined as vision loss that cannot be corrected by medical or surgical treatments, or conventional eyeglasses, according to the American Academy of Ophthalmology. The Centers for Disease Control and Prevention’s Vision and Eye Health Surveillance System (VEHSS) estimates that there are more 243,000 Illinois residents experiencing vision loss.

Since its inception, the ISPB Low Vision Equipment Reimbursement Program has provided thousands of patients with no-cost low vision aids and glasses. These tools help children succeed in the classroom, adults to continue to work, and seniors to remain independent.

Since 1916, ISPB has developed relationships with community partners, many of whom treat underserved communities, to identify low-income patients. These partners find the most effective low vision equipment and ensure that it fits the needs of the patient before applying for the ISPB reimbursement program. Current ISPB partners include Lurie Children’s Hospital, The Rosenbloom Center at the Illinois Eye Institute, The Center for Sight and Hearing, and The Chicago Lighthouse.

“Unfortunately, low vision equipment, which can be very expensive, is not covered by health insurance, including Medicare and Medicaid,” said Elyse Fineman, executive director at ISPB. “Thanks to the generous support of Horizon, we can now expand our program to provide these tools to those in need.”

“Through our work with the Thyroid Eye Disease (TED) community, we’ve seen the important role that accessibility tools and adaptive technology can play for those living with low vision,” said Matt Flesch, vice president, communications and patient advocacy, Horizon Therapeutics. “However, those tools and resources can be incredibly cost prohibitive. These grants will help remove some of those financial barriers and help people who are blind or living with low vision access necessary equipment to live more independent lives.”

Horizon also recently supported the launch of the newly redesigned Prevent Blindness resource, “Living Well With Low Vision.” The site, designed for patients, care partners and professionals, offers a wide variety of resources including patient guides, a low vision news feed, database of Low Vision Resource Directories, and much more.

For more information on the ISPB Low Vision Equipment Reimbursement Program, visit here. (Patients should contact partnering clinics directly for an appointment.) To visit the Living Well With Low Vision resource, go here.

Press Releases

Recent Posts

Economy Is Slowing but Remains Resilient

Prices for services still rising, while goods level off: NRF economist.

1 day ago

The Pros and Cons of Virtual Assistants and More of Your Questions Answered

Plus, what’s the secret to an employee review that’s actually effective?

1 day ago

Mastering Sales & Style: 6 Lessons Learned from TV

Art may imitate life but that doesn’t mean it still can’t teach us a few…

1 day ago

A 30-Year Optical Veteran Who Grew Up Within 30 Miles of the Community She Serves With 3 Generations of Women

And little gets this 30-year cancer survivor down but cleaning the 1,500 frames on their…

2 days ago

87% of You Don’t Use Employment Contracts

Often citing the employee handbook is enough. Guess our next question will be “Do You…

2 days ago

This website uses cookies.